These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 17467570)

  • 1. WASH in India: need for innovation.
    The Lancet Regional Health-Southeast Asia
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100336. PubMed ID: 38076714
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of Civil Society in Mobilizing Human Rights Struggles for Essential Medicines: A Critique from HIV/AIDS to COVID-19.
    Sekalala S; Rawson B
    Health Hum Rights; 2022 Dec; 24(2):177-189. PubMed ID: 36579304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the therapeutic value of new medicines marketed in Australia.
    Vitry AI; Shin NH; Vitre P
    J Pharm Policy Pract; 2013; 6():2. PubMed ID: 24764537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first decade of antiretroviral therapy in Africa.
    Ford N; Calmy A; Mills EJ
    Global Health; 2011 Sep; 7():33. PubMed ID: 21958478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 6. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotech in post-TRIPS India.
    Ramani SV; Pradhan P; Ravi M
    Nat Biotechnol; 2005 Jan; 23(1):18-9. PubMed ID: 15637608
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent laws. Report urges leeway for developing world.
    Couzin J; Bagla P
    Science; 2002 Sep; 297(5588):1791. PubMed ID: 12228696
    [No Abstract]   [Full Text] [Related]  

  • 9. Patent threat in emerging economies shifts to biotech.
    Jayaranam K
    Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
    [No Abstract]   [Full Text] [Related]  

  • 10. Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing.
    Ford N; 't Hoen E; von Schoen-Angerer T
    Drug Discov Today; 2007 May; 12(9-10):349-51. PubMed ID: 17467570
    [No Abstract]   [Full Text] [Related]  

  • 11. [Industry and pharmaceutical research in Italy. How to make up for lost time].
    Mortari U
    Recenti Prog Med; 2006 Nov; 97(11):634-9. PubMed ID: 17252720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perspectives on the development of biologics.
    Kramer BC
    PM R; 2011 Jun; 3(6 Suppl 1):S132-5. PubMed ID: 21703570
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.